期刊文献+

融合蛋白Epo-Tpo(C)的表达及初步活性检测 被引量:3

Eukaryotic expression,purification and analysis of the fusion protein of Epo-Tpo(C)
原文传递
导出
摘要 目的 进一步研究促血小板生成素Tpo的功能 ,探讨新型Epo的可能性。 方法 构建了融合蛋白Epo Tpo(C)的真核表达载体 ,在CHO细胞中表达融合蛋白 ,染料亲合柱Blue SepharoseCL 6B初步纯化 ,网织红细胞计数法体内测活并测定了体内半衰期和融合蛋白对大鼠肾衰模型的疗效。结果 初步纯化的融合蛋白体内活性比ELISA结果高 2 0 % ,半衰期为 12h ,比标准Epo长近5 0 % ,对大鼠肾衰模型有良好的疗效。结论 Tpo富糖基化的C端结构域能显著延长Epo的半衰期 ,融合蛋白Epo Tpo(C) Objective To further elucidate the function of Tpo(C) and create a new type of Epo.Methods Tpo(C) was linked to Epo to produce a fusion protein\_\_Epo\|Tpo(C).The fusion gene was expressed in CHO cell.After selection with G418,Epo\|Tpo(C)\|expressing cell lines was obtained.The supernatant had 15 U/ml Epo activity.The results of PCR and Southern Blotting indicated the fusion gene was fused into the genome.RT\|PCR and RNA Dot Blotting analysis found the Epo\|Tpo(C) mRNA.The supernatant was purified with Blue Sepharose CL\|6B.Results The rate of recovery was 94%.The \%in vivo\% activity tested by reticulocytes was 20% higher than ELISA.The half\|life was about 12 hours while the Epo standard sample had half\|life of 8 hours tested with ELISA in rat.Conclusion The results proved that Tpo(C) could protect Epo and improve its function.The fusion protein had satisfactory effect in the model of rat renal failure.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2001年第1期5-8,共4页 Chinese Journal of Experimental and Clinical Virology
关键词 血小板生成素 红细胞生成素 融合蛋白质类 真核表达 Thrombopoietin(Tpo) Erythropietin(Epo) Fusion protein Eucaryon expression
  • 相关文献

参考文献1

二级参考文献2

共引文献1

同被引文献35

  • 1马清均主编.生物技术药物[M].北京:化学工业出版社,2002.50-51.
  • 2Motoo Yamasaki, Makoto Asano, Masami Okabe, et al. Modification of recombinant human granulocyte colony-stimulatlng factor and its derivative ND28 with polyethylene glycol. J Biochem, 1994, 115:814 -- 819.
  • 3Gombotz, et al. Prolonged release of GM-CSF ,2001, US6274175.
  • 4Breton J, Gurevich V. Characterization of a natural disulfide-linked conjugate of pro-utopians ( pro-utopians ) with albumin.Fibrinolysis, 1990,3(4) : 160.
  • 5Chuang VT, Kragh-Hansen U, Otagiri M, et al. Pharmaceutial strategies utilizing recombinant human serum albumin.Pharmaceutical Research,2002,19(5) :569 -- 577.
  • 6Stephen D, Gillies, Kin-Ming Lo, et al. Improved circulating half-life and efficacy of an anfibody-interleukin 2 immunoncytokin based on reduced intracellular proteolysis, Clinical Cancer Research,2002,8:210 -- 216.
  • 7Kobayashi K, Nakamura N, Sumi A, et al. The development of recombinant human serum albumin .Ther Apher, 1998,2(4) :257 --262.
  • 8Patrice Yeh, Didier Landais, Marc Lemaitre, et al. Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci. USA , 1992,89 : 1904 -- 1908.
  • 9Marques J A, George J K, Smith IJ, et al. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb Haemost, 2001,86(3) :902 -- 908.
  • 10Sheffield W P, Smith I J, Syed S, et al. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis,2001,12(6) :433- 443.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部